In the United States, the Glutaraldehyde price trend took a positive turn. Prices went up by x.xxx due to limited supply and consistent demand. Production issues in various chemical sectors reduced the availability of Glutaraldehyde, putting upward pressure on prices. The slowdown in production reflects a wider industrial downturn, made worse by weak industrial demand and ongoing uncertainties related to tariffs that have affected manufacturing confidence.
Investor worries grew due to actions taken by the Trump administration. These included attempts to lower U.S. prescription drug prices to match prices abroad, new tariffs on pharmaceuticals, and reductions in funding for health research and Medicaid. These actions have created uncertainty for pharmaceutical stocks and directly affected the demand for Glutaraldehyde in its main end-use sector—healthcare and pharmaceuticals—where consumption remained low. On the other hand, demand from industries like wastewater treatment, leather tanning, and clinical research stayed...
